194 related articles for article (PubMed ID: 11307802)
1. Fibrinolytic variables in patients with recurrent venous thrombosis: a prospective cohort study.
Crowther MA; Roberts J; Roberts R; Johnston M; Stevens P; Skingley P; Patrassi GM; Sartori MT; Hirsh J; Prandoni P; Weitz JI; Gent M; Ginsberg JS
Thromb Haemost; 2001 Mar; 85(3):390-4. PubMed ID: 11307802
[TBL] [Abstract][Full Text] [Related]
2. [The fibrinolytic system in patients with dilated myocardiopathy].
Fernández P; Marín F; Marco P; Roldán V; García MC; Martínez JG; Sogorb F; Calatayud R
Sangre (Barc); 1996 Oct; 41(5):351-5. PubMed ID: 9026920
[TBL] [Abstract][Full Text] [Related]
3. Risk of venous thromboembolism recurrence: high negative predictive value of D-dimer performed after oral anticoagulation is stopped.
Palareti G; Legnani C; Cosmi B; Guazzaloca G; Pancani C; Coccheri S
Thromb Haemost; 2002 Jan; 87(1):7-12. PubMed ID: 11848459
[TBL] [Abstract][Full Text] [Related]
4. Effect of ACE inhibition on the fibrinolytic system in patients requiring coronary artery bypass grafting.
Walter T; Szabo S; Kazmaier S; Suselbeck T; Borggrefe M; Hoffmeister HM
Thorac Cardiovasc Surg; 2009 Sep; 57(6):368-71. PubMed ID: 19707983
[TBL] [Abstract][Full Text] [Related]
5. Anticoagulation period in idiopathic venous thromboembolism. How long is enough?
Farraj RS
Saudi Med J; 2004 Jul; 25(7):848-51. PubMed ID: 15235686
[TBL] [Abstract][Full Text] [Related]
6. Systemic haemostasis after intermittent pneumatic compression. Clues for the investigation of DVT prophylaxis and travellers thrombosis.
Giddings JC; Morris RJ; Ralis HM; Jennings GM; Davies DA; Woodcock JP
Clin Lab Haematol; 2004 Aug; 26(4):269-73. PubMed ID: 15279664
[TBL] [Abstract][Full Text] [Related]
7. The significance of hypofibrinolysis for the risk of recurrence of venous thromboembolism. Duration of Anticoagulation (DURAC) Trial Study Group.
Schulman S; Wiman B
Thromb Haemost; 1996 Apr; 75(4):607-11. PubMed ID: 8743187
[TBL] [Abstract][Full Text] [Related]
8. Fibrinolytic activity in multiple myeloma.
Yağci M; Sucak GT; Haznedar R
Am J Hematol; 2003 Dec; 74(4):231-7. PubMed ID: 14635202
[TBL] [Abstract][Full Text] [Related]
9. Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments.
De Stefano V; Za T; Rossi E; Vannucchi AM; Ruggeri M; Elli E; Micò C; Tieghi A; Cacciola RR; Santoro C; Gerli G; Vianelli N; Guglielmelli P; Pieri L; Scognamiglio F; Rodeghiero F; Pogliani EM; Finazzi G; Gugliotta L; Marchioli R; Leone G; Barbui T;
Haematologica; 2008 Mar; 93(3):372-80. PubMed ID: 18268279
[TBL] [Abstract][Full Text] [Related]
10. Factors influencing the recanalisation rate of deep venous thrombosis .
Jezovnik MK; Poredos P
Int Angiol; 2012 Apr; 31(2):169-75. PubMed ID: 22466983
[TBL] [Abstract][Full Text] [Related]
11. Cerebral venous congestion as indication for thrombolytic treatment.
Tsai FY; Kostanian V; Rivera M; Lee KW; Chen CC; Nguyen TH
Cardiovasc Intervent Radiol; 2007; 30(4):675-87. PubMed ID: 17573553
[TBL] [Abstract][Full Text] [Related]
12. Eprosartan effect on fibrinolytic/hemostatic variables in arterial hypertension: a comparative study to losartan.
Makris TK; Stavroulakis G; Papadopoulos DP; Krespi P; Hatzizacharias A; Zilidis A; Tsoukala C; Votteas VE
Drugs Exp Clin Res; 2004; 30(3):125-32. PubMed ID: 15366789
[TBL] [Abstract][Full Text] [Related]
13. Altered endothelial function following the Fontan procedure.
Binotto MA; Maeda NY; Lopes AA
Cardiol Young; 2008 Feb; 18(1):70-4. PubMed ID: 18093358
[TBL] [Abstract][Full Text] [Related]
14. A metabolic syndrome independent association between overweight, fibrinolysis impairment and low-grade inflammation in young women with venous thromboembolism.
Salobir B; Sabovic M
Blood Coagul Fibrinolysis; 2006 Oct; 17(7):551-6. PubMed ID: 16988550
[TBL] [Abstract][Full Text] [Related]
15. Predictive value of D-dimer test for recurrent venous thromboembolism after anticoagulation withdrawal in subjects with a previous idiopathic event and in carriers of congenital thrombophilia.
Palareti G; Legnani C; Cosmi B; Valdré L; Lunghi B; Bernardi F; Coccheri S
Circulation; 2003 Jul; 108(3):313-8. PubMed ID: 12847064
[TBL] [Abstract][Full Text] [Related]
16. Plasma fibrinolytic capacity in renal transplant recipients: effect of steroid-free immunosuppression therapy.
Sartori MT; Rigotti P; Marchini F; Spiezia L; Baldan N; Furian L; Varvarikis C; Girolami A
Transplantation; 2003 Apr; 75(7):994-8. PubMed ID: 12698086
[TBL] [Abstract][Full Text] [Related]
17. Livedoid vasculopathy associated with plasminogen activator inhibitor-1 promoter homozygosity (4G/4G) treated successfully with tissue plasminogen activator.
Deng A; Gocke CD; Hess J; Heyman M; Paltiel M; Gaspari A
Arch Dermatol; 2006 Nov; 142(11):1466-9. PubMed ID: 17116837
[TBL] [Abstract][Full Text] [Related]
18. [Fibrinolytic system and a central retinal vein thrombosis].
Malukiewicz-Wiśniewska G
Klin Oczna; 1998; 100(3):175-8. PubMed ID: 9814003
[TBL] [Abstract][Full Text] [Related]
19. A critical review of the evidence supporting a relationship between impaired fibrinolytic activity and venous thromboembolism.
Prins MH; Hirsh J
Arch Intern Med; 1991 Sep; 151(9):1721-31. PubMed ID: 1888237
[TBL] [Abstract][Full Text] [Related]
20. Fibrinolysis and the risk of venous and arterial thrombosis.
Meltzer ME; Doggen CJ; de Groot PG; Rosendaal FR; Lisman T
Curr Opin Hematol; 2007 May; 14(3):242-8. PubMed ID: 17414214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
